Get the Stockscreener App
4.74
3.07%
-0.15
Pre-market:
4.65
-0.09
-1.90%
Cns Pharmaceuticals Inc stock is traded at $4.74, with a volume of 8,882.
It is down -3.07% in the last 24 hours and down -4.24% over the past month.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
See More
Previous Close:
$4.89
Open:
$4.79
24h Volume:
8,882
Relative Volume:
0.01
Market Cap:
$6.93M
Revenue:
-
Net Income/Loss:
$-16.49M
P/E Ratio:
-0.16
EPS:
-29.6295
Net Cash Flow:
$-15.24M
1W Performance:
-3.07%
1M Performance:
-4.24%
6M Performance:
-33.15%
1Y Performance:
-51.07%
1-Day Range:
$4.7301
$5.01
1-Week Range:
$4.4012
$5.10
52-Week Range:
$1.90
$12.36
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
4.74 | 6.93M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
Why did CNSP stock surge 330% today? - MSN
CNSP Q1 2026 Earnings: Wider Than Expected Loss, No Revenue Reported; Stock Rises 3.6%Estimate Revision Count - newsline.com
CNS Pharmaceuticals (CNSP) Tests Key Levels After Modest GainBreadth Thrust - newsline.com
Relmada Therapeutics Appoints CNS Drug Development Veteran - GlobeNewswire
CNS Pharmaceuticals Company Profile & Introduction - Moomoo
CNS Pharmaceuticals (NASDAQ: CNSP) Highlights Oversubscribed $22.5M Financing, Growth Strategy in Investor Presentation - TradingView
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Cash Burn and Pipeline ChallengesPretax Income Report - newsline.com
CNS Pharmaceuticals Highlights Oversubscribed $22.5 Million Financing and Growth Strategy - citybuzz -
CNS Pharmaceuticals CFO, Steve O'Loughlin, Highlights Company's Recent $22.5M Financing in Virtual Investor "What This Means" Segment - ACCESS Newswire
Biotech CFO breaks down oversubscribed $22.5M raise and strategy shift - Stock Titan
NRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS Therapeutics - Quiver Quantitative
CNS Pharmaceuticals (CNSP) Shows Resilience with 2% Gain, Testing Key ResistanceSeasonality Effect - newsline.com
CNSP Q1 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Quality Score - newsline.com
CNS Pharmaceuticals Inc. (CNSP) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Advances - newsline.com
CNS Pharmaceuticals Surges 11% as Biotech Sector Shows Renewed InterestDeath Cross - The Legal Advocate
CNS Pharmaceuticals (CNSP) Faces Selling Pressure as Shares Decline Over 5%Total Put Call - The Legal Advocate
CNS (CNSP) Suffers -4.49% Decline on Heavy Selling 2026-05-28Initial Balance - newsline.com
Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight - GlobeNewswire Inc.
[EFFECT] CNS Pharmaceuticals, Inc. SEC Filing - Stock Titan
CNS Pharmaceuticals (NASDAQ: CNSP) registers 9.79M resale shares from May private placement - Stock Titan
CNSP SEC FilingsCNS Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress - Bluefield Daily Telegraph
Insider Buying: Faith Charles Acquires Shares of CNS Pharmaceuti - GuruFocus
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals director Faith L. Charles buys $34,001 in stock - Investing.com
CNSP | CNS Pharmaceuticals, Inc. Common Insider Trading - Quiver Quantitative
CNS Pharmaceuticals raises $22.5M to advance new biotech therapies and strategic growth. - Pluang
[Form 4] CNS Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
CNS Pharmaceuticals Registers 9.79 Million Shares for Selling Holders - Moomoo
CNS Pharmaceuticals (CNSP) registers 9.79M shares including prefunded warrants - Stock Titan
cns pharmaceuticals inc Earnings dates - RTTNews
NRXP: Advanced CNS drug pipeline, reduced net loss, and expanded clinical footprint in Q1 2026 - TradingView
CNS Pharmaceuticals, Inc. announced that it has received $22.515858 million in funding from ADAR1 Capital Management, LLC, Ikarian Capital, LLC, Stonepine Capital Management LLC, Nazare Partners and other investors - marketscreener.com
Stonepine (CNSP) reports 159,790 shares; 9.9% position disclosed - Stock Titan
Maxim Group Maintains CNS Pharmaceuticals(CNSP.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Addex Therapeutics (ADXN.SW) Jumps 6.7% as CNS Drug Pipeline Advances - Meyka
CNSP Poised for Growth Through Strategic Initiatives - GuruFocus
CNS Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CNSP's Financial Outlook After Recent Fundraising - GuruFocus
CNS Pharmaceuticals, Inc. Q1 2026 Financials and Corporate Strategy Update – 10-Q Report Highlights - Minichart
CNS Pharmaceuticals : CNSP - 24/7 Wall St.
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transforma - PharmiWeb.com
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress - ACCESS Newswire
Biotech CNS Pharmaceuticals secures $22.5M to buy neurology, oncology drugs - Stock Titan
CNS Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CNS Pharmaceuticals (CNSP) widens Q1 loss but secures $22.5M private placement - Stock Titan
ACADIA Pharmaceuticals stock (US0042251084): Biotech decline amid CNS focus - AD HOC NEWS
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6 - 24/7 Wall St.
TradingKey - TradingKey
CNS Pharmaceuticals Inc expected to post a loss of $5.37 a shareEarnings Preview - TradingView
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):